{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:47:31Z","timestamp":1790754451963,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015236","name":"Lupin Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015236","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nmd.2024.104464","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T19:45:57Z","timestamp":1727293557000},"page":"104464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Recommendations of an expert group for the cardiac assessment of non-dystrophic myotonia adult patients treated with mexiletine"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-4098","authenticated-orcid":false,"given":"Savine","family":"Vicart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josselin","family":"Duchateau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Sellal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Deharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bassez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Labombarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.104464_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/awp294","article-title":"The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment","volume":"133","author":"Matthews","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2024.104464_bib0002","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.nmd.2023.01.007","article-title":"Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing","volume":"33","author":"Vivekanandam","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.104464_bib0003","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2024.104464_bib0004","first-page":"1598","article-title":"Muscle channelopathies: the nondystrophic myotonias and periodic paralyses","volume":"19","author":"Statland","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.nmd.2024.104464_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103489","article-title":"The myotonic dystrophy type 1 drug development pipeline: 2022 edition","volume":"28","author":"Pascual-Gilabert","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.nmd.2024.104464_bib0006","article-title":"Pr\u00e9cis de Rythmologie","author":"Wilkin","year":"2023","journal-title":"Rythmologie"},{"key":"10.1016\/j.nmd.2024.104464_bib0007","first-page":"665","article-title":"[Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine]","volume":"139","author":"Pouget","year":"1983","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.nmd.2024.104464_bib0008","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). NAMUSCLA (mexil\u00e9tine): https:\/\/has-sante.fr\/jcms\/p_3135571\/fr\/namuscla-mexiletine; [accessed May 10, 2023]."},{"key":"10.1016\/j.nmd.2024.104464_bib0009","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.acvd.2024.03.001","article-title":"Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy","volume":"117","author":"Wahbi","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.nmd.2024.104464_bib0010","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s13311-018-00678-0","article-title":"Skeletal muscle channelopathies","volume":"15","author":"Phillips","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2024.104464_bib0011","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1212\/WNL.0b013e3181ed9e96","article-title":"Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder","volume":"75","author":"Lion-Francois","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.104464_bib0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11940-020-00644-2","article-title":"Treatment updates for neuromuscular channelopathies","volume":"22","author":"Jitpimolmard","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.nmd.2024.104464_bib0013","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ana.20905","article-title":"Cold extends electromyography distinction between ion channel mutations causing myotonia","volume":"60","author":"Fournier","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2024.104464_bib0014","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.20241","article-title":"Electromyography guides toward subgroups of mutations in muscle channelopathies","volume":"56","author":"Fournier","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2024.104464_bib0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.nmd.2013.05.001","article-title":"Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotonias","volume":"23","author":"Morrow","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.104464_bib0016","series-title":"Comprehensive physiology","first-page":"761","article-title":"Channelopathies of skeletal muscle excitability","author":"Cannon","year":"2015"},{"key":"10.1016\/j.nmd.2024.104464_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102329","article-title":"Drug repurposing in skeletal muscle ion channelopathies","volume":"68","author":"Altamura","year":"2023","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.nmd.2024.104464_bib0018","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ejhpharm-2015-000839","article-title":"A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia","volume":"23","author":"D'Mello","year":"2016","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.nmd.2024.104464_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJM198701013160106","article-title":"Mexiletine","volume":"316","author":"Campbell","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.104464_bib0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/europace\/euac087","article-title":"Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review","volume":"24","author":"van der Ree","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.nmd.2024.104464_bib0021","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nmd.2024.104464_bib0022","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.104464_bib0023","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.82.4.1106","article-title":"Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials","volume":"82","author":"Coplen","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.nmd.2024.104464_bib0024","unstructured":"Lupin Europe GmbH. Summary of product characteristics: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/namuscla-epar-product-information_en.pdf; [accessed 13 October 2023]."},{"key":"10.1016\/j.nmd.2024.104464_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/JND-200582","article-title":"Targeted therapies for skeletal muscle ion channelopathies: systematic review and steps towards precision medicine","volume":"8","author":"Desaphy","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2024.104464_bib0026","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.hrthm.2020.05.043","article-title":"Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up","volume":"17","author":"Vio","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.nmd.2024.104464_bib0027","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1001\/jama.2018.18020","article-title":"Effect of mexiletine on muscle stiffness in patients with Nondystrophic myotonia evaluated using aggregated N-of-1 Trials","volume":"320","author":"Stunnenberg","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2024.104464_bib0028","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2024.104464_bib0029","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","article-title":"Efficacy and safety of mexiletine in non-dystrophic myotonias: a randomised, double-blind, placebo-controlled, cross-over study","volume":"31","author":"Vicart","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.104464_bib0030","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fneur.2020.00300","article-title":"Long-term safety and usefulness of mexiletine in a large cohort of patients affected by non-dystrophic myotonias","volume":"11","author":"Modoni","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2024.104464_bib0031","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3389\/fneur.2020.00593","article-title":"Genotype-phenotype correlations and characterization of medication use in inherited myotonic disorders","volume":"11","author":"Meyer","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2024.104464_bib0032","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/ejhg.2015.125","article-title":"SCN4A variants and Brugada syndrome: phenotypic and genotypic overlap between cardiac and skeletal muscle sodium channelopathies","volume":"24","author":"Bissay","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2024.104464_bib0033","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s00415-020-10328-1","article-title":"Non-dystrophic myotonias: clinical and mutation spectrum of 70 German patients","volume":"268","author":"Vereb","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2024.104464_bib0034","article-title":"The clinical, myopathological, and genetic analysis of 20 patients with non-dystrophic myotonia","volume":"13","author":"Wang","year":"2022","journal-title":"Front Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662400960X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662400960X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T12:09:01Z","timestamp":1731672541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089662400960X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":34,"alternative-id":["S096089662400960X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.104464","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations of an expert group for the cardiac assessment of non-dystrophic myotonia adult patients treated with mexiletine","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.104464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104464"}}